Deciphera Pharmaceuticals | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (12)

View All

Latest Posts

About This Stock More About This Stock
The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More
Article By: Benzinga
Sunday, January 23, 2022 2:45 PM EDT
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that encompassed the JPM Healthcare conference.
In this article: ABT, JNJ, RHHBY, UCBJY, ZGNX, VRTX, ZLAB, CUE, DCPH, ETON
Read
691 Stocks Are Down Over 50% This Year
Article By: Fred Fuld III
Sunday, December 5, 2021 4:59 PM EDT
It may be hard to believe because the stock market has been in such an uptrend this year, but there are some interesting statistics for stock performance year-to-date.
In this article: DCPH, STNE, DOYU, RIDE, ROOT
Read
Week In Review: Three China In-Licensing Deals Add Up To $662 Million
Article By: ChinaBio® Today
Saturday, April 3, 2021 2:56 PM EDT
Simcere Pharma of Nanjing announced a $292 million agreement to develop a proposed Kazia Therapeutics treatment for glioma in Greater China. Qihan Biotechnology raised $67 million in a Series A++ round to advance its portfolio of cell therapies.
In this article: SCR, SBMFF, SVA, GILD, BYSI, ZLAB, DCPH, KZIA
Read
4 Biotechs That Could Be Potential Acquisition Targets In 2021
Article By: Zacks Investment Research
Thursday, December 17, 2020 10:24 PM EDT
Stocks of these companies have not fully recovered from the stock-market crash in March 2020, suggesting attractive valuations.
In this article: BMRN, QURE, RGNX, DCPH
Read
Week In Review: BioKangtai Acquires China Rights To AstraZeneca's COVID-19 Vaccine
Article By: ChinaBio® Today
Saturday, August 8, 2020 12:13 PM EDT
BioKangtai, a Guangdong vaccine company, in-licensed rights to develop, manufacture, and market AstraZeneca's COVID-19 vaccine in China. Biogen announced a $2 billion deal to partner Denali Therapeutics' potential Parkinson's Disease therapy.
In this article: AZN, BIIB, VTGN, GTHX, ZLAB, DNLI, DCPH
Read
All Posts

Latest Tweets for $DCPH

No tweets yet!

PARTNER HEADLINES